Trevi Therapeutics

$3.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+0.98%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell TRVI and other stocks, options, and ETFs commission-free!

About TRVI

Trevi Therapeutics, Inc. Common Stock, also called Trevi Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT. The listed name for TRVI is Trevi Therapeutics, Inc. Common Stock.

CEO
Jennifer L. Good
Employees
17
Headquarters
New Haven, Connecticut
Founded
2011
Market Cap
56.80M
Price-Earnings Ratio
Dividend Yield
Average Volume
23.18K
High Today
$3.09
Low Today
$3.04
Open Price
$3.04
Volume
5.65K
52 Week High
$8.50
52 Week Low
$1.33

Collections

TRVI Earnings

-$0.63
-$0.42
-$0.21
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
-$0.40 per share

You May Also Like